JP2024537323A - 抗グリピカン3抗体 - Google Patents
抗グリピカン3抗体 Download PDFInfo
- Publication number
- JP2024537323A JP2024537323A JP2024522070A JP2024522070A JP2024537323A JP 2024537323 A JP2024537323 A JP 2024537323A JP 2024522070 A JP2024522070 A JP 2024522070A JP 2024522070 A JP2024522070 A JP 2024522070A JP 2024537323 A JP2024537323 A JP 2024537323A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- antibody
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025006663A JP2025061426A (ja) | 2021-10-15 | 2025-01-17 | 抗グリピカン3抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/124182 | 2021-10-15 | ||
| CN2021124182 | 2021-10-15 | ||
| PCT/CN2022/125725 WO2023061505A1 (en) | 2021-10-15 | 2022-10-17 | Anti-glypican 3 antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006663A Division JP2025061426A (ja) | 2021-10-15 | 2025-01-17 | 抗グリピカン3抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024537323A true JP2024537323A (ja) | 2024-10-10 |
| JP2024537323A5 JP2024537323A5 (cg-RX-API-DMAC7.html) | 2025-11-10 |
Family
ID=85988149
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024522070A Pending JP2024537323A (ja) | 2021-10-15 | 2022-10-17 | 抗グリピカン3抗体 |
| JP2025006663A Pending JP2025061426A (ja) | 2021-10-15 | 2025-01-17 | 抗グリピカン3抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025006663A Pending JP2025061426A (ja) | 2021-10-15 | 2025-01-17 | 抗グリピカン3抗体 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20240409663A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4527465A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2024537323A (cg-RX-API-DMAC7.html) |
| CN (3) | CN118488970A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023061505A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024061305A1 (zh) * | 2022-09-22 | 2024-03-28 | 上海美雅珂生物技术有限责任公司 | Gpc3抗体药物偶联物及其应用 |
| CN119894935B (zh) * | 2022-09-30 | 2026-06-19 | 信立泰(成都)生物技术有限公司 | 抗gpc3单克隆抗体/双特异性抗体或其抗原结合片段及其用途 |
| WO2025045242A1 (zh) * | 2023-09-01 | 2025-03-06 | 信立泰(成都)生物技术有限公司 | 一种靶向gpc3的双特异性抗体或抗原结合片段及其用途 |
| EP4775226A1 (en) * | 2023-09-05 | 2026-07-15 | Lepu Biopharma Co., Ltd. | Antibody drug conjugate targeting gpc3 and use thereof |
| KR20250116580A (ko) * | 2024-01-24 | 2025-08-01 | 국립암센터 | Gpc3에 특이적으로 결합하는 신규 항체를 이용한 키메라 항원 수용체 t 세포 |
| WO2026016998A1 (zh) * | 2024-07-15 | 2026-01-22 | 北京剂泰医药科技有限公司 | 编码针对GPC3和CD3双特异性抗体的mRNA分子 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006006693A1 (ja) * | 2004-07-09 | 2006-01-19 | Chugai Seiyaku Kabushiki Kaisha | 抗グリピカン3抗体 |
| JP2017522861A (ja) * | 2014-05-22 | 2017-08-17 | ジェネンテック, インコーポレイテッド | 抗gpc3抗体及びイムノコンジュゲート |
| CN109021108A (zh) * | 2018-08-27 | 2018-12-18 | 南京医科大学 | 抗gpc3全人源化抗体、其嵌合抗原受体细胞及应用 |
| JP2025006663A (ja) * | 2023-06-29 | 2025-01-17 | 積水化学工業株式会社 | 情報処理システム、情報処理方法及びプログラム |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6420140B1 (en) | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
| EP1411118B1 (en) * | 2001-06-22 | 2008-09-03 | Chugai Seiyaku Kabushiki Kaisha | Cell proliferation inhibitors containing anti-glypican-3 antibody |
| WO2004022597A1 (ja) * | 2002-09-04 | 2004-03-18 | Chugai Seiyaku Kabushiki Kaisha | Gpc3の血中可溶化n端ペプチドに対する抗体 |
| AU2008275985B2 (en) * | 2007-07-17 | 2013-09-19 | E. R. Squibb & Sons, L.L.C. | Monoclonal antibodies against Glypican-3 |
| CN101633693A (zh) * | 2009-08-24 | 2010-01-27 | 中国人民解放军第二军医大学 | 一种抗gpc3的单克隆抗体 |
| US9926377B2 (en) * | 2014-05-22 | 2018-03-27 | Genentech, Inc. | Anti-GPC3 antibodies and immunoconjugates |
| CN105037540A (zh) * | 2015-05-13 | 2015-11-11 | 北京比洋生物技术有限公司 | 抗磷脂酰肌醇蛋白聚糖3全人源抗体 |
| AU2016304060B2 (en) * | 2015-08-03 | 2022-09-29 | Crage Medical Co., Limited | Antibody against glypican-3 and application thereof |
| CN109153719B (zh) * | 2016-03-15 | 2022-12-30 | 中外制药株式会社 | 使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法 |
| EP3615574B1 (en) * | 2017-04-26 | 2026-06-24 | Eureka Therapeutics, Inc. | Constructs specifically recognizing glypican 3 and uses thereof |
| CN109988240B (zh) * | 2017-12-29 | 2022-06-28 | 安源医药科技(上海)有限公司 | 抗gpc-3抗体及其用途 |
| CN114340671A (zh) * | 2019-08-01 | 2022-04-12 | R.P.谢勒技术有限责任公司 | 对gpc3特异性的抗体及其使用方法 |
-
2022
- 2022-10-17 CN CN202280083725.4A patent/CN118488970A/zh active Pending
- 2022-10-17 CN CN202411431728.XA patent/CN119080937A/zh active Pending
- 2022-10-17 JP JP2024522070A patent/JP2024537323A/ja active Pending
- 2022-10-17 EP EP25152478.1A patent/EP4527465A3/en active Pending
- 2022-10-17 WO PCT/CN2022/125725 patent/WO2023061505A1/en not_active Ceased
- 2022-10-17 US US18/700,228 patent/US20240409663A1/en active Pending
- 2022-10-17 CN CN202411431725.6A patent/CN118994403B/zh active Active
- 2022-10-17 EP EP22880441.5A patent/EP4416187A1/en active Pending
-
2025
- 2025-01-16 US US19/026,082 patent/US20250154280A1/en active Pending
- 2025-01-17 JP JP2025006663A patent/JP2025061426A/ja active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006006693A1 (ja) * | 2004-07-09 | 2006-01-19 | Chugai Seiyaku Kabushiki Kaisha | 抗グリピカン3抗体 |
| JP2017522861A (ja) * | 2014-05-22 | 2017-08-17 | ジェネンテック, インコーポレイテッド | 抗gpc3抗体及びイムノコンジュゲート |
| CN109021108A (zh) * | 2018-08-27 | 2018-12-18 | 南京医科大学 | 抗gpc3全人源化抗体、其嵌合抗原受体细胞及应用 |
| JP2025006663A (ja) * | 2023-06-29 | 2025-01-17 | 積水化学工業株式会社 | 情報処理システム、情報処理方法及びプログラム |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250154280A1 (en) | 2025-05-15 |
| CN118488970A (zh) | 2024-08-13 |
| EP4527465A3 (en) | 2025-07-09 |
| CN118994403A (zh) | 2024-11-22 |
| WO2023061505A1 (en) | 2023-04-20 |
| US20240409663A1 (en) | 2024-12-12 |
| EP4527465A2 (en) | 2025-03-26 |
| CN119080937A (zh) | 2024-12-06 |
| EP4416187A1 (en) | 2024-08-21 |
| CN118994403B (zh) | 2025-04-01 |
| JP2025061426A (ja) | 2025-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN118994403B (zh) | 抗磷脂酰肌醇蛋白聚糖3抗体 | |
| KR102649942B1 (ko) | 클라우딘 18.2를 표적화하는 항체-약물 콘쥬게이트 | |
| KR20210125511A (ko) | 항-cd228 항체 및 항체-약물 컨쥬게이트 | |
| US20250313632A1 (en) | Anti-b7-h3 antibodies and uses thereof | |
| WO2023155925A1 (en) | Anti-5t4 antibodies and uses thereof | |
| US12194106B2 (en) | Antibodies targeting LIV-1 and uses thereof | |
| US20250011427A1 (en) | Anti-cd3 antibodies with cross-reactivity to human and cynomolgus proteins | |
| WO2024125417A1 (en) | Bispecific antibodies targeting pd1 and vegf | |
| US20250109200A1 (en) | Antibodies and antibody-drug conjugates targeting claudin 6 | |
| WO2025011462A1 (en) | Single domain antibodies for gprc5d | |
| HK40113267A (en) | Anti-glypican 3 antibodies | |
| HK40117975A (en) | Anti-b7-h3 antibodies and uses thereof | |
| HK40117975B (en) | Anti-b7-h3 antibodies and uses thereof | |
| HK40112932A (en) | Anti-5t4 antibodies and uses thereof | |
| WO2025260010A2 (en) | Anti-nectin-4 antibodies and uses of the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20251017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251030 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20251119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260803 |